Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the
treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.